Category Innovation/ R&D

Special Report: WHO Board Sets Review Of 10-Year Effort To Boost Medicines Access, Affordability

Once considered a breakthrough in negotiations to address problems of making cutting-edge medical products and research available to poor countries, the decade-old World Health Organization Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA) is now undergoing review, with the WHO Executive Board calling for a report on the initiative and plans for its future next year.

Geneva Health Campus: New Home For Global Fund, GAVI, Unitaid In 2018

The construction of a new building to host the Global Fund to Fight AIDS, Tuberculosis and Malaria and other key players in the area of global health is well under way in Geneva. The “Campus Santé” (Health Campus) is expected to open its doors at the beginning of 2018. The hosts of the building will be tenants, while the investment costs are borne by Crédit Suisse, a prominent Swiss investment bank.

The Problem With Rare Diseases: R&D Lacking, High Prices, Discrimination, IP Issues

Over 6,000 rare diseases, those affecting very small populations, have been documented in the world. For those affected, treatments are mostly non-existent, and if they do exist, are not affordable. An event last week gathered a number of stakeholders, including rare disease organisations, the World Health Organization and the pharmaceutical industry to discuss the particular issue of rare diseases. The case of rare diseases is an exacerbated example of research, pricing, accessibility and affordability.

New Policies On Technology Transfer In China: Granting More Autonomy To Universities

According to a recent circular released by the Chinese ministries of education, and science and technology, universities established by the state have autonomy in technology transfer (see the original news here). Unless the scientific and technological achievements concern national security, national interests, and major public interests, it is unnecessary to report to the ministry of finance or management department. All income gained from the technology transfer belongs to the universities.

Patentability Of Some Biotech Uncertain In Europe As Examination, Opposition Suspended

The patentability of plants or animals that have been obtained by natural occurrence such as selection and crossing has been a recurrent issue discussed at the European Patent Office (EPO). A recent notice from the European Commission challenged a ruling by the EPO Enlarged Board of Appeal on such patents, prompting yet more discussions in the organisation. In the meantime, all examination and opposition on such patents have been halted at the EPO. Industry is concerned that the EPO ruling might be questioned, and warns of effects on innovation, harm to applicants. Civil society is concerned about a non-transparent process.

US Chamber International IP Index: US, Europe At Top; India Needs A Push

The United States Chamber of Commerce today released its fifth annual International IP Index, which makes the case for the positive impact of intellectual property on economies. The United States scored highest, followed by top European economies and Japan. And near the bottom was India, despite recent efforts to accept the IP system. Separately, the report assesses international trade rules for IP and argues for nations to negotiate "TRIPS-plus" agreements.

Government-Financed R&D Declining; Private Sector, Tax Incentives Rise, OECD Finds

A new set of science and technology indicators shows that the business sector is expected to remain the driving force behind research and development growth, according to the Organisation for Economic Co-operation and Development (OECD). The OECD released its main science and technology indicators today and found that government-financed research and development expenditures have been declining for some years.

Confidential Draft Of WHO Cancer Resolution Shows Remaining Issues IP-Related

The latest version of a draft resolution on addressing the global rise of cancer negotiated last week at the World Health Organization shows that remaining points are intellectual property-related, but there seems to be agreement on referencing trade flexibilities in the text, even from the United States, and a common goal of lowering prices of treatment. WHO members tried to reach common language during the Executive Board in January but time ran out and discussions are expected to continue until the annual World Health Assembly in May.

Cancer Resolution Not Agreed Yet At WHO; Work Needed On IP Issues

World Health Organisation members tried to agree on a draft resolution on cancer during the WHO Executive Board but consensus escaped them, in particular on intellectual property issues, according to sources. The text is expected to be discussed informally with a view to reaching common language on the remaining issues by the annual World Health Assembly in May.